Israeli scientists find antibody that neutralizes coronavirus

Israel Institute for Biological Research completes groundbreaking study proving new antibody is effective against coronavirus.

Arutz Sheva Staff

fighting coronavirus

In the past two days, the Israel Institute for Biological Research (IIBR), has completed a groundbreaking scientific development, determining an antibody that neutralizes the coronavirus (SARS-COV-2), the Defense Ministry announced Tuesday evening.

This scientific breakthrough has three key parameters:

1. The antibody is monoclonal, new and refined, and contains an exceptionally low proportion of harmful proteins
2. The institute has demonstrated the ability of the antibody to neutralize the coronavirus
3. The antibody was specifically tested on the aggressive coronavirus

The Defense Ministry stated: “Based on comprehensive scientific publications from around the globe, it appears that the IIBR is the first institution to achieve a scientific breakthrough that meets all three of the aforementioned parameters simultaneously. This is a result of the institute’s great experience and the unique capabilities of its scientists.”

The IIBR is currently pursuing a patent for its development, after which it will contact international manufactures.

“It should be emphasized that this scientific achievement has the potential to progress towards a treatment for corona patients, and that it is not a vaccine for wide use. This is an important milestone, which will be followed by a series of complex tests and a process of regulatory approvals. This being said, the scientists at the institute believe that the nature of this breakthrough could lead to a shortening of the process, which could span over several months,” the Defense Ministry concluded.
<
>

May 6, 2020 | 3 Comments »

Subscribe to Israpundit Daily Digest

Leave a Reply

3 Comments / 3 Comments

  1. “Israel’s coronavirus is on the decline: Lockdown, mother nature or math?
    COVID-19 has a periodicity of a classic Gaussian bell-curve shape wherever it appears, according to Ran Namerode, chairman of Redworth Capital Group.

    Government action had nothing to do with the country’s success in the battle against the novel coronavirus, according to MK Ofer Shelah (Yesh Atid-Telem).
    “Clearly, this virus behaves in a way that is related to weather, genetics and especially the age of each country’s inhabitants,” he said Wednesday at the Knesset.
    Shelah is chairman of the Knesset Coronavirus Committee.
    While there could be any number of reasons for the recent decline, it could just be “a normal distribution,” according to Ran Namerode, chairman of Redworth Capital Group, which focuses on global real estate, medical devices, movies productions and more.
    COVID-19 has a periodicity of a classic Gaussian bell-curve shape wherever it appears, he told The Jerusalem Post.
    In probability theory, the Gaussian distribution is a continuous function that approximates the exact binomial distribution of events.
    “This bell’s life cycle is around six to eight weeks, with its peak appearing after about two or four weeks from the time when incidents begin to occur at a substantial rate,” Namerode said.
    In Israel, the disease first appeared in substantial numbers around March 10. The peak arrived on April 2, when the country had 765 new cases in 24 hours. Then, as Namerode predicted in a Post article in March, it began to decline to only a few new cases per day toward the end of April.
    The World Health Organization has reported accumulated numbers of coronavirus cases in the world since the onset of the pandemic, and the numbers therefore appear to be constantly growing, Namerode said. However, if one looks at the pandemic by state or territory, the pattern is consistent in every one, and the virus begins to decline after around four weeks, he added.
    “The first cases of morbidity in Hubei, China, appeared in late November,” Namerode said. “But a daily rate of 100 cases began around January 20. In mid-February, the daily rate reached thousands. However, by March 6, it dropped back to about 100 cases per day and has been continuously declining since then.”
    “Within seven weeks the disease appeared, peaked and was suppressed almost completely,” he said. “When we talk about the end of the pandemic, what I mean is around 100 or 200 cases per day. These numbers do not represent a challenge to any health system. When the level has declined to these numbers, it is the end of the disaster.”
    In South Korea, which implemented a strategy of large-scale testing instead of massive quarantine, dozens of daily new cases started to appear around February 20. By March 3, the daily rate had reached a peak of approximately 850 new cases. By March 15, it stabilized at an average of less than 100 new cases per day.
    Italy was the first and one of the hardest-hit European countries. On February 22, more than 50 new cases appeared there. On March 21, the country peaked with approximately 6,500 new cases daily. Today, the country has fewer than 2,000 cases per day and is in a pattern of daily decline.Coronavirus cases in Germany increased from March 10 to April 1. Four weeks later, the country has about 1,000 new diagnoses daily. The country has 83 million people, so its 1,000 cases per day is equivalent to about 100 in Israel.
    Switzerland, Spain, the Netherlands and nearly all other countries show similar patterns.
    “Since the basis of this model is its locality, an analysis of the US should be conducted at a state level rather than the countrywide one,” Namerode said.
    After his first piece appeared in the Post, he was “criticized by so many people,” Namerode said. “But apparently it works in every country. Each territory behaved exactly like this.”
    The bell curve’s length and number of deaths relates to how efficient each country was at implementing social distancing and other measures, he said. But there is no big difference between those countries that took extreme or medium measures, he added.
    “This is not about biology or politics,” Namerode said, adding that his expertise is not in immunology nor infectious diseases.
    “Numbers, however, can provide an explanation to natural phenomena even in places where the relevant science cannot,” he told the Post. As a businessman, he said, he is used to looking at numbers, analyzing them and then drawing data-driven conclusions.
    “I looked at the numbers and could see a pattern, exactly how I would analyze market behaviors or trends,” he said.
    Namerode is not the only businessman or mathematician to look for similar patterns. Nobel Prize laureate Michael Levitt successfully forecast the slowdown in the rate of infection in mainland China.
    By looking at statistics emerging on the number of people infected and the number of deaths, Levitt identified a bounded growth pattern, showing that instead of the rate of infection increasing exponentially, it started to tail off.
    Levitt also predicted that Israel would have few deaths.
    Shelah said the coronavirus “loves Western European and North American countries.”
    “There are 13 states with 100 dead per million,” he told the Knesset on Wednesday, noting that they were all in Western Europe, the US and Canada. In contrast, he said, the number of dead per million in Greece is half of that of Israel, and in Cyprus only 12 people have died. Moreover, in the West Bank, where three million Palestinians live, only two deaths connected to coronavirus were reported, he added.
    Namerode did not substantiate Shelah’s hypothesis. But given the level of disease Israel eventually witnessed, he believes the country overreacted and will pay too steep an economic price.” From today’s Jerusalem Post.

  2. Shmuel Mohalever Said:

    The effectiveness of this for treatment of c.v. has yet to be tested on either animals or humans. The testing process could take more than a year before final approval is reached.

    Pls. volunteer to be the first guinea pig 😛

  3. The effectiveness of this for treatment of c.v. has yet to be tested on either animals or humans. The testing process could take more than a year before final approval is reached.